Publication:
The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site

Simple item page
dc.contributor.authorOrzol, Paulina
dc.contributor.authorHolcakova, Jitka
dc.contributor.authorNekulova, Marta
dc.contributor.authorNenutil, Rudolf
dc.contributor.authorVojtesek, Borivoj
dc.contributor.authorCoates, Philip J.
dc.date.accessioned2020-04-20T08:56:11Z
dc.date.available2020-04-20T08:56:11Z
dc.date.issued2015
dc.description.abstractp63 and p73, the two other members of the p53 family, were identified almost 15 years ago. Here, we review their potential use for diagnosis, prognosis and prediction of response to therapy in various cancers. The two genes show distinct expression patterns in both normal and cancer tissues and each gene gives rise to multiple protein isoforms with different activities, including those with tumour-suppressor or oncogenic effects. Despite such complexity, some common themes emerge; p63 is commonly overexpressed as the ΔNp63 isoform and sometimes associated with TP63 amplification, whereas p73 is often reduced (by methylation or gene loss), or there is an increase in the ratio of ΔNp73 to TAp73. These generalisations do not apply universally; TAp63 is overexpressed in haematological malignancies, TP63 mis-sense mutations have been reported in squamous cancers and TP63 translocations occur in lymphomas and some lung adenocarcinomas. There are associations with disease prognosis and response to specific therapies in individual cancer types for both p63 and p73, making their analysis of clinical relevance. We also discuss their utility for aiding in differential diagnosis, which has been demonstrated for p63, but not yet for p73. Throughout, we highlight the discrepant nature of many studies due to the variable methodologies employed, the lack of systematic evaluation of isoforms and the problems of poor antibody characterization and crossreactions within the p63/p73 family. Finally, we emphasize the value of recently developed isoformspecific reagents that have clear advantages for the study of p63 and p73 experimentally and clinically.es
dc.formatapplication/pdfes
dc.format.extent19es
dc.identifier.citationHistology and Histopathology, Vol. 30, n.º 5 (2015)
dc.identifier.doihttps://doi.org/10.14670/HH-30.503
dc.identifier.issn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/90055
dc.languageenges
dc.publisherF. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histologíaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectp53es
dc.subjectp63es
dc.subjectp73es
dc.subjectCanceres
dc.subject.otherCDU::5 - Ciencias puras y naturales::57 - Biología::576 - Biología celular y subcelular. Citologíaes
dc.titleThe diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer sitees
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Orzol-30-503-521-2015.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.30, nº5 (2015)